Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et studie af SHR-2173 hos deltagere med systemisk lupus erythematosus

24. september 2026 opdateret af: Guangdong Hengrui Pharmaceutical Co., Ltd

Et Multicenter, Randomiseret, Dobbeltblindt, Placebokontrolleret Fase II Klinisk Studie til Vurdering af Effektivitet og Sikkerhed af SHR-2173 Injektion hos Patienter med Systemisk Lupus Erythematosus

This study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and a 12-week safety follow-up period. Approximately 245 SLE patients will be included.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

248

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100005
        • Rekruttering
        • Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
        • Ledende efterforsker:
          • Xiaofeng Zeng
        • Kontakt:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200127
        • Rekruttering
        • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Ledende efterforsker:
          • Liangjing Lv
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male and female participants aged 18 through 65 years (including boundary value)at the time of screening.
  2. The Body Mass Index (BMI) ≥18 kg/m ² at the time of screening.
  3. Diagnosed with SLE for at least 6 months prior to screening.
  4. ANA≥1:80, or anti-dsDNA antibodies and/or anti-Sm antibodies above the upper limit of the normal range as determined by a central laboratory at the time of screening.
  5. High disease activity at screening and at baseline.
  6. Currently receiving at least one or more of the following standard therapies for SLE at stable doses: oral corticosteroids (OCS), antimalarial drugs, and conventional immunosuppressants.
  7. Participants thoroughly understand the content, process and possible adverse reactions before the trial, and voluntarily sign the written informed Consent Form (ICF).
  8. Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take contraceptive measures as specified in the protocol.

Exclusion Criteria:

  1. The presence of any of the following medical histories or comorbidities: a) Severe lupus-related kidney disease and/or kidney damage; b) Active neuropsychiatric SLE occurred 6 months prior to screening; c) Autoimmune, inflammatory or joint diseases other than SLE and LN that may interfere with the interpretation of the test results or clinical assessment, including but not limited to rheumatoid arthritis, overlap syndrome, psoriasis/psoriatic arthritis, eczema, inflammatory bowel disease, and any other vasculitis; d) There was catastrophic or severe antiphospholipid syndrome within 12 months prior to screening; e) Have a history of progressive multifocal leukoencephalopathy (PML); f) Have a history of organ transplantation.
  2. Use any of the following medications /treatments or participate in a clinical trial: a) Previously received gene therapy such as CAR-T or T-cell Engager (TCE) ; b) Received anti-CD20 monoclonal antibody within 6 months and other B-cell or plasma cell depletion treatments within 6 to 12 months prior to randomization; c) Received biologic therapy targeting BAFF, APRIL or interferon receptor within 12 weeks prior to randomization; d) Received Alkylating agents within 12 weeks prior to randomization; e) Received any other biological agents for the treatment of SLE within 12 weeks prior to randomization; f) Received inhibitors of Janus kinase (JAK), Bruton tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2) within 12 weeks prior to randomization; g) Received intra-articular, intramuscular or intravenous corticosteroid for SLE within 4 weeks prior to randomization; h) Received a live/attenuated live vaccine within 4 weeks prior to randomization or planned to receive it during the trial period.
  3. The presence of the following tumor risks or accompanied by other poorly controlled serious or chronic diseases: a) Suffering from malignant tumors or having a history of malignant tumors; b) Accompanying other poorly controlled serious or chronic diseases during or at the time of screening, including but not limited to endocrine diseases, cardiovascular diseases, neurological/mental disorders, kidney diseases, severe digestive system diseases, severe respiratory system diseases, neurological diseases, and other serious liver, gallbladder, metabolic or lymphatic system diseases, etc.
  4. Infection-related medical history and examinations: a) Herpes zoster infection meets one of the following conditions: 1) A history of systemic herpes zoster, such as disseminated herpes zoster, herpetic encephalitis or ocular herpes zoster involving the retina; 2) Recurrent herpes zoster that has occurred twice or more within two years; 3) The herpes zoster infection has not completely subsided within 12 weeks before screening; b) Tuberculosis (TB) or occult tuberculosis infection; c) A history of primary immunodeficiency, splenectomy, and any potential conditions that make participants susceptible to infection; d) A history of repeated infections requiring hospitalization and intravenous antibiotics; e) Hospitalization and/or intravenous anti-infective treatment were required within 8 weeks prior to randomization, or any infection that required oral anti-infective treatment within 2 weeks prior to randomization; f) Positive test results for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody, Treponema pallidum antibody or human immunodeficiency virus (HIV); If the test result is negative for HBsAg but positive for hepatitis B core antibody (HBcAb), regardless of whether the hepatitis B surface antibody (HBsAb) is positive or negative, HBV-DNA testing is required to determine the situation: if HBV-DNA is positive, participants should be excluded. Participants can be included if HBV-DNA is negative.
  5. General situation: a) Pregnant or lactating women; b) Having a history of alcohol abuse or illegal drug abuse within one year prior to screening; c) Individuals with allergic constitutions, or those known to be intolerant or allergic to any component of the investigational drug; d) Participants who have undergone major surgeries within the 3 months prior to screening, or those who plan to undergo major surgeries during the trial period; e) Investigators determine that there are circumstances that affect the safety and efficacy evaluation of the investigational drug, or other circumstances not appropriate for participation in this study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: SHR-2173 Injektionsgruppe

SHR-2173 injection in different doses.

Placebo komparator: SHR-2173-injektionsplacebogruppe

SHR-2173 injection placebo.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Andelen af deltagere, der opnår Systemic Lupus Erythematosus Responder Index-4 (SRI-4) i uge 24.
Tidsramme: I uge 24.
I uge 24.

Sekundære resultatmål

Resultatmål
Tidsramme
Andelen af deltagere, der opnår SRI-4.
Tidsramme: Op til uge 48.
Op til uge 48.
Andelen af deltagere, der opnår British Isles Lupus Assessment Group (BILAG) baseret Composite Lupus Assessment (BICLA).
Tidsramme: Op til uge 48.
Op til uge 48.
Andelen af deltagere med et fald på ≥ 4 point fra baseline i SLE Disease Activity Index 2000 (SLEDAI-2K).
Tidsramme: Op til uge 48.
Op til uge 48.
Andelen af deltagere, der opnår SRI-4 med lavdosis-kortikosteroider i protokollen.
Tidsramme: Op til uge 48.
Op til uge 48.
Andelen af deltagere med en daglig prednisondosis (eller ækvivalent) på ≤ 7,5 mg (begrænset til dem med baselinekortikosteroider > 7,5 mg/dag).
Tidsramme: Op til uge 48.
Op til uge 48.
Ændring fra baseline i patientens globale vurdering (PGA).
Tidsramme: Op til uge 48.
Op til uge 48.
Andelen af deltagere, der opnår Lupus Lav Sygdomsaktivitetstilstand (LLDAS) i protokollen.
Tidsramme: Op til uge 48.
Op til uge 48.
Andelen af deltagere, der opnår Definitions of Remission In SLE (DORIS) i protokollen.
Tidsramme: Op til uge 48.
Op til uge 48.
Ændring fra baseline i niveauet af anti-dsDNA antistof.
Tidsramme: Op til uge 48.
Op til uge 48.
Ændring fra udgangspunkt i niveauet af komplement (C3, C4).
Tidsramme: Op til uge 48.
Op til uge 48.
Ændring fra baseline i niveauet af CD19+B-celler.
Tidsramme: Op til uge 48.
Op til uge 48.
Ændring fra baseline i Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) i protokollen.
Tidsramme: Op til uge 48.
Op til uge 48.
Ændringer fra baseline i SLE-specifik livskvalitet (SLEQOL) i protokollen.
Tidsramme: Op til uge 48.
Op til uge 48.
Adverse events, vital signs, physical examinations, laboratory tests, 12-lead electrocardiograms, etc.
Tidsramme: The entire process of the trial , about two years.
The entire process of the trial , about two years.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. april 2026

Primær færdiggørelse (Anslået)

1. marts 2028

Studieafslutning (Anslået)

1. november 2028

Datoer for studieregistrering

Først indsendt

28. november 2025

Først indsendt, der opfyldte QC-kriterier

9. december 2025

Først opslået (Faktiske)

23. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. september 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • SHR-2173-202

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner